Table 1.
Demographic characteristics and clinical data of the study cohort at baseline.
| Number of patients | 220 |
|---|---|
| Men/female, n | 150:70 |
| Age, years ± SD | 71.3 ± 9.2 |
| Diabetes duration, years ± SD | 12.4 ± 4.6 |
| BMI, Kg/m2 ± SD | 29.5 ± 3.0 |
| Smoking (current), n (%) | 61 (27.7) |
| Smoking (former), n (%) | 68 (30.9) |
| Never smoked, n (%) | 91 (41.4) |
| Hypertension, n (%) | 120 (54.5) |
| Hypercholesterolemia, n (%) | 100 (45.4) |
| CAD, n (%) | 102 (46.4) |
| CVD, n (%) | 45 (20.4) |
| Lipid-lowering agent | 178 (80.9) |
| ACE inhibitor or ARB | 165 (75.0) |
| ABI, ± SD | 0.39 ± 0.1 |
| Rutherford II-4, n (%) | 121 (55.0) |
| Rutherford III-5, n (%) | 99 (45.0) |
| WIfI010, n (%) | 99 (45.0) |
| WIfI020, n (%) | 35 (15.9) |
| WIfI110, n (%) | 62 (28.2) |
| WIfI120, n (%) | 107 (48.6) |
| HbA1c, % ± SD | 8.8 ± 1.5 |
| FBG, mg/dL ± SD | 114.1 ± 19.8 |
| Total cholesterol, mg/dL ± SD | 204.1 ± 29.3 |
| LDL cholesterol, mg/dL ± SD | 100.7 ± 19.4 |
| Triglycerides, mg/dL ± SD | 212.2 ± 36.9 |
| Creatinine, mg/dL ± SD | 1.4 ± 0.4 |
| eGFR, mL/min/1.73m2 ± SD | 64.4 ± 14.6 |
| Ca, mg/dL ± SD | 9.5 ± 0.8 |
| Ph, mg/dL ± SD | 3.7 ± 0.8 |
| Vitamin D, ng/mL ± SD | 48.5 ± 15.9 |
| Klotho, pg/mL ± SD | 403.1 ± 179.3 |
| FGF23 pg/mL ± SD | 59.4 ± 17.5 |
Data are reported as means (standard deviation) for continuous variables and numbers (percentages) for categorical variables. BMI Body Mass Index; CAD Coronary Artery Disease; CVD Cerebrovascular Disease; ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; ABI Ankle Brachial Index; WIfI Wound, Ischemia, foot Infection; FBG Fasting Blood Glucose; eGFR estimated Glomerular Filtration Rate; Ca Calcium; Ph Phosphorus; FGF23 Fibroblast Growth Factor 23.